Neuroblastoma is a pediatric solid tumor that originates from embryonic neural crest cells. The MYCN gene locus is frequently amplified in unfavorable neuroblastomas, and the gene product promotes the progression of neuroblastomas. However, the molecular mechanisms by which MYCN amplification contributes to stem cell-like states of neuroblastoma remain elusive. In this study, we show that MYCN and its cis-antisense gene, NCYM, form a positive feedback loop with OCT4, a core regulatory gene maintaining a multipotent state of neural stem cells. We previously reported that NCYM is co-amplified with the MYCN gene in primary human neuroblastomas and that the gene product promotes aggressiveness of neuroblastoma by stabilization of MYCN. In 36 MYCN-amplified primary human neuroblastomas, OCT4 mRNA expression was associated with unfavorable prognosis and was correlated with that of NCYM. The OCT4 protein induced both NCYM and MYCN in human neuroblastoma cells, whereas NCYM stabilized MYCN to induce OCT4 and stem cell-related genes, including NANOG, SOX2, and LIN28. In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells. All-trans retinoic acid treatment reduced MYCN, NCYM, and OCT4 expression, accompanied by the decreased amount of OCT4 recruited onto the intron 1 region of MYCN. Knockdown of NCYM or OCT4 inhibited formation of spheres of neuroblastoma cells and promoted asymmetric cell division in MYCN-amplified human neuroblastoma cells. These results suggest that the functional interplay between MYCN, NCYM, and OCT4 contributes to aggressiveness of MYCN-amplified human neuroblastomas. N euroblastoma is a pediatric solid tumor that arises in sympatho-adrenal tissues.
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(1) Amplification of the MYCN oncogene is frequently observed in unfavorable neuroblastomas, (2) and aberrant expression of MYCN contributes to neuroblastoma progression. (3) The transcription factor MYCN regulates a wide variety of biological phenomena, including cell-cycle progression, apoptosis, differentiation, and stemness. (4, 5) MYCN transgenic mice spontaneously develop neuroblastomas, (3) but unlike human MYCN-amplified neuroblastomas, the mice rarely have metastatic tumors. Recently, we reported that NCYM, a MYCN cis-antisense gene, encodes a protein that functions as an onco-promoting factor. (6) The coding sequence of NCYM is not evolutionally conserved in mice, and the NCYM gene is co-amplified with MYCN in human primary neuroblastomas. (6) The MYCN protein directly targets NCYM for transcriptional activation, whereas NCYM stabilizes MYCN protein, forming a positive autoregulatory loop. (6, 7) Expression of NCYM caused metastatic tumors in MYCN ⁄ NCYM double transgenic mice and inhibited apoptotic cell death. (6) However, these results do not rule out the possibility that NCYM is involved in other cellular phenotypes to promote the aggressiveness of neuroblastoma.
Neuroblastomas originate from neural crest cells that differentiate into multiple cell lineages. (8) Some neuroblastoma cells retain multipotency and highly express stem cell-related genes, such as OCT4 (9) and LIN28. (10) Intermediate (I)-type neuroblastoma cells highly express OCT4 and differentiate into neuroblastic (N)-type or substrate adherent (S)-type cells in response to retinoic acid or BrdU treatment, respectively. serve as progenitors of tumor-derived endothelial cells, promoting neovascularization of the tumors. (9) Furthermore, OCT4 is expressed in side-population cells of neuroblastoma. (12) Despite these correlations between OCT4 expression and the stem cell-like state of neuroblastomas, the functional roles of OCT4 in neuroblastoma pathogenesis remain unclear. In this study, we investigated the biological and clinical significance of OCT4 in neuroblastomas and found that the newly evolved network between MYCN, NCYM, and OCT4 regulates aggressiveness of human neuroblastomas.
Materials and Methods
Immunofluorescence analysis. BE(2)-C and SK-N-AS cells were grown on coverslips and transfected with indicated shRNAs. Cells were fixed in 4% paraformaldehyde for 15 min at room temperature, blocked in 3% BSA, stained with the indicated antibodies, and examined with a laser scanning confocal microscope (DMI 4000B; Leica, Wetzlar, Germany).
Asymmetric cell division assay. We tested whether neuroblastoma cells showed asymmetric distribution of nuclear mitotic apparatus protein (NuMA). Asymmetric distributions of NuMA to one side of the cell were counted during mitotic stages. The spindle apparatus were also stained with anti-tubulin-a antibody to avoid false results caused by uneven dyeing. The antibodies used were anti-NuMA (Novus Biologicals, Littleton, CO, USA), and anti-tubulin-a (Thermo Fisher Scientific, Wilmington, DE, USA).
Statistical analysis. All data were presented as the mean AE standard deviation and were obtained from three independent experiments. Statistical significance in the clinical data was calculated using the log-rank test, v 2 -test, and Student's t-test. Hazard ratios were calculated using univariate and multivariate Cox regression analysis. Statistical analyses were undertaken using JMP 9 (SAS Institute Japan, Tokyo, Japan). Statistical significance was set at P < 0.05.
More detailed descriptions of the Material and Methods are described in Document S1.
Results
High expression of OCT4 associated with poor prognoses in MYCN-amplified human neuroblastomas. To examine the prognostic significance of OCT4 mRNA expression in human neuroblastoma, total RNA was extracted from 36 MYCN-amplified and 67 MYCN-non-amplified primary neuroblastomas and subjected to quantitative real-time RT-PCR. MYCN amplification was examined as previously described [13] . Kaplan-Meier analysis showed that high levels of OCT4 mRNA expression were significantly associated with poor outcomes in MYCNamplified human neuroblastomas (Fig. 1a) , but not in MYCNnon-amplified human neuroblastomas (Fig. 1b) .
Expression levels of OCT4 correlated with prognostic factors. We next checked the relationship between the expression of OCT4 and prognostic factors. The expression levels of OCT4 were significantly correlated with International Neuroblastoma Staging System (INSS) stage, Shimada pathology, and expression of NCYM and MYCN in MYCN-amplified primary neuroblastomas (Table 1 ). In addition, univariate Cox regression analysis of 36 MYCN-amplified primary neuroblastomas indicated that high levels of OCT4 mRNA expression tended to correlate with poor prognosis (Table S1 ). Multivariate Cox regression analysis also revealed that OCT4 mRNA expression was not independent of NCYM and MYCN mRNA expression in MYCN-amplified primary neuroblastomas (Table S2) .
NCYM induced OCT4 via induction of MYCN. We next examined the factors that predict OCT4 expression in primary neuroblastomas by multiple regression analysis (Table S3 ). The expression levels of NCYM, NANOG, KLF4, and c-MYC and MYCN amplification significantly contributed to the prediction of OCT4 expression in primary neuroblastomas (Table S3) . Furthermore, the expression levels of NCYM mRNA were positively correlated with those of OCT4 and NANOG, whereas with MYCN-amplified neuroblastomas according to relative OCT4 expression levels (n = 36; high, n = 14; low, n = 22). P-value by log-rank test.
(b) Overall survival of patients with MYCN-non-amplified neuroblastomas according to relative OCT4 expression levels (n = 67; high, n = 22; low, n = 45). P-value by log-rank test. OCT4 mRNA expression designated high or low according to the average value. KLF4 expression was inversely correlated with that of MYCN and NCYM (Table S4) . These results prompted us to assess whether NCYM regulates OCT4 as well as stem cell-related genes in human neuroblastoma cells. Overexpression of NCYM or MYCN, but not c-MYC, induced OCT4 mRNA expression (Figs S1,S2) as well as NANOG, LIN28, and SOX2, whereas neither NCYM nor MYCN enhanced c-MYC or KLF4 (Fig. S1 ). Knockdown of NCYM decreased OCT4 and MYCN expression at both mRNA and protein levels (Fig. 2a,b) , and suppressed their promoter activities (Fig. 2c) . In addition, the expression levels of a stem cell-related protein CD133 were also downregulated by NCYM knockdown (Fig. S3A) . A previous report suggested that MYCN is directly recruited onto the distal enhancer of human OCT4. (14) We thus checked the recruitment of MYCN onto putative E-box sites found in human OCT4 enhancer regions (Fig. 2d ). Endogenous MYCN protein was recruited onto the distal enhancer region (Fig. 2d ,e, #1), but not in the proximal enhancer region (Fig. 2d,e, #2 ). Knockdown of NCYM diminished MYCN binding to the distal enhancer of OCT4 (Fig. 2e) . Together, these results suggest that NCYM regulates OCT4 transcription by induction of MYCN.
In sharp contrast to human neuroblastoma cells, overexpression of NCYM in mice did not induce stem cell-related genes either in vitro (Fig. S4) or in vivo (Fig. S5) . Furthermore, the E-box at the distal enhancer region of OCT4 is not evolutionally conserved among species (Fig. S6A) .
Transcription of MYCN in human neuroblastoma directly stimulated by OCT4. OCT4, SOX2, and NANOG form core networks in embryonic stem (ES) cells by their mutual transcriptional regulations. (15) We thus examined whether OCT4 regulates MYCN ⁄ NCYM transcription in human neuroblastoma cells. In BE(2)-C MYCN-amplified neuroblastoma cells, shRNA-mediated knockdown of OCT4 downregulated MYCN at both the mRNA and protein levels (Fig. 3a,b) . CD133 was also suppressed by OCT4 knockdown (Fig. S3B) . Although OCT4 knockdown decreased NCYM mRNA expression, it showed marginal effects on the expression of NCYM protein (Fig. 3a,  b) . In MYCN non-amplified SK-N-AS cells, overexpression of OCT4 induced the expression and promoter activities of MYCN and NCYM (Fig. S7) , as well as the expression of NANOG and SOX2 (Fig. S8A) . In BE(2)-C cells, OCT4 knockdown suppressed the promoter activities of OCT4 and MYCN, whereas it did not affect NCYM promoter activity (Fig. 3c) . These results suggest that OCT4 may not directly affect NCYM transcription at the endogenous expression level. Overexpression of OCT4 enhanced activities of MYCN reporter constructs containing the intron 1 region of MYCN (Fig. 3d) . We found two putative OCT4 binding sites within the intron 1 region, and generated luciferase reporter constructs harboring mutations in the OCT4 binding sites (Fig. 3e) . Mutations in the upstream OCT4 binding sequence diminished OCT4-mediated enhancement of MYCN promoter activity, whereas MYCN promoter constructs containing the WT upstream OCT4 site sustained the response to OCT4 overexpression (Fig. 3e) . Chromatin immunoprecipitation assay showed that OCT4 was directly recruited onto the intron 1 region of MYCN (Fig. 3f,g,  #3) . We also observed the recruitment of OCT4 to the promoter of MYCN (Fig. 3f,g, #2) , although the OCT4 site in the MYCN promoter was not responsible for OCT4-mediated enhancement of MYCN promoter activity (Fig. 3e) . We next checked the conservation of the OCT4 binding site within intron 1 among species, and found that it is mostly conserved among primates, but not in mice (Fig. S6B ).
OCT4 is downregulated on differentiation of neuroblastoma cells. BE(2)-C I-type neuroblastoma cells are stem cell-like cells that show the ability to differentiate into N-type cells in response to retinoic acid treatment (11) and MYCN expression is downregulated during the differentiation. (11) We assessed the expression of NCYM and OCT4 in BE(2)-C Itype cells treated with all-trans retinoic acid (ATRA) (Fig. 4a,b) . As reported previously, (11) BE (2)-C I-type cells differentiated into N-type cells with marked neurite extensions (Fig. 4a,b) , accompanied by a rapid decrease of MYCN expression (Fig. 4c,d ). The decrease of MYCN was followed by the downregulation of NCYM, OCT4, NANOG, and SOX2 (Figs 4c,d ,S8B,C), whereas no significant changes were observed in the expression levels of NANOG mRNA (Fig.  S8B) . A neural maker GAP43 was induced in the ATRA-treated neuroblastomas cells (Fig. S8C) . In good accordance with the strong correlation in primary tumors (Table S4) , NCYM and OCT4 expression showed similar expression patterns in ATRA-treated BE(2)-C cells (Fig. 4c,d) . Furthermore, ATRA treatment decreased MYCN binding to the distal enhancer of OCT4 (Fig. 4e) and OCT4 binding to the intron 1 region of MYCN (Fig. 4f) . Therefore, retinoic acid-induced neuronal differentiation abrogated the positive autoregulatory loops formed by MYCN, NCYM, and OCT4 through the simultaneous downregulation of their expression.
Self-renewal of neuroblastoma cells maintained by OCT4 and NCYM. We next examined whether OCT4 and NCYM contributes to self-renewal of neuroblastoma cells. Knockdown of NCYM or OCT4 in BE(2)-C cells inhibited formation of spheres of neuroblastoma cells and cellular invasion, whereas the cell proliferation was not significantly changed within 3 days after shRNA transduction (Fig. 5) . Izumi et al. (16) reported that neuroblastoma cells have stem cell-like characteristics showing both asymmetric and symmetric cell divisions in vitro and that MYCN suppresses the asymmetric cell division (ACD). Consistent with the previous report, (16) immunocytochemistry analyses showed a high percentage of cells exhibiting ACD in SK-N-AS MYCN-non-amplified cells compared with BE(2)-C MYCN-amplified cells (Fig. S9) . The shRNA-mediated knockdown of NCYM or OCT4 significantly increased the number of cells exhibiting ACD in BE(2)-C cells ( Fig. 5f,g ). Collectively, these results suggest that NCYM and OCT4 maintain self-renewal of human neuroblastoma cells.
Discussion
Here, we found that OCT4 promotes aggressiveness of MYCNamplified neuroblastoma cells by forming a positive regulatory loop with MYCN ⁄ NCYM (Fig. 6) . Despite a correlation between OCT4 expression and a stem cell-like state of neuroblastomas, the clinical significance of OCT4 in neuroblastomas has remained elusive. In this study, we found that OCT4 was correlated with NCYM expression and undifferentiated pathological characteristics in Shimada pathology. Furthermore, the expression levels of OCT4 were associated with unfavorable outcomes in MYCN-amplified tumors, but not in MYCN-non-amplified tumors. Previous studies showed that MYCN expression was inversely correlated with c-MYC in neuroblastoma (17) and that low expression levels of KLF4 mRNA were associated with poor neuroblastoma outcome. (18) Our results showed that NCYM was positively correlated with NA-NOG expression and was inversely correlated with KLF4 and c-MYC. As overexpression of OCT4 induced NANOG mRNAs, the correlation between NANOG and MYCN ⁄ NCYM in neuroblastomas may be explained by their common upstream regulator, OCT4. In vitro experiments showed that overexpression of NCYM induced OCT4, SOX2, and NANOG, but not c-MYC or KLF4. Therefore, among stem cell-related genes, NCYM mainly regulated the transcription of genes related to maintenance of pluripotency of ES cells (19) (20) (21) in human neuroblastoma cells. The NCYM protein stabilized MYCN to stimulate OCT4 transcription, whereas OCT4 induced NCYM and MYCN through direct transcriptional activation of MYCN. Therefore, MYCN, NCYM, and OCT4 cooperate to induce each other, resulting in keeping their own expression at high levels and maintaining self-renewal of cells in MYCN-amplified neuroblastomas. Differentiation-inducing therapy by retinoic acid treatment has improved the overall survival of patients with MYCN-amplified neuroblastomas, (22) and ATRA treatment abrogated the mutual transcriptional regulations between MYCN, NCYM, and OCT4, inducing neuroblastoma cell differentiation. The ATRA treatment rapidly decreased NCYM mRNA within 24 hours, but the protein levels of NCYM were hardly downregulated compared with those of MYCN or OCT4. Therefore, the NCYM protein may be relatively more stable than MYCN or OCT4 proteins. Previous studies have shown that OCT4-positive neuroblastoma cells have resistant potency to conventional therapy (12) and multipotency to differentiation. (9) Thus, the functional interplay between MYCN ⁄ NCYM and OCT4 may contribute to maintenance of the multipotent status of OCT4-positive cells and the disruption of the MYCN ⁄ NCYM-OCT4 network could be a good therapeutic strategy for aggressive tumors.
Pezzolo et al. (9) reported that 2-30% of OCT4-positive cells were detected in approximately 90% of neuroblastoma samples (21 of 23). Thus, in contrast to other cancer stem cells, (23) the stem cell-like populations of neuroblastomas may not be small. In addition, high OCT4 expression was correlated with poor prognoses in patients with MYCN-amplified neuroblastomas, but not MYCN-non-amplified tumors, although the expression levels of OCT4 in MYCN-non-amplified tumors were comparable to those in MYCN-amplified tumors. These results indicate that OCT4 requires MYCN amplification to promote aggressiveness of neuroblastomas. As NCYM inhibits apoptosis in MYCN-amplified tumors, (6) NCYM may be required for efficient proliferation of multipotent OCT4-positive cells. Therefore, variable amounts of OCT4-positive cells in MYCNamplified tumors may reflect the different percentages of proliferative stem cell-like cells, influencing the prognoses of patients.
Previous reports have shown the physiological roles of OCT4 in the transcriptional regulation of MYC family members in various species. (24) (25) (26) OCT4 stimulates MYC transcription for cell proliferation in human and mouse ES cells (24, 25) and activates myc transcription for cell survival during zebrafish gastrulation. (26) In the present study, we found the pathological significance of OCT4 for MYCN transcription in human neuroblastoma cells. The OCT4 binding sequence in MYCN intron 1 is not present in mice, but it is mostly conserved in other mammals. Although the E-box responsible for MYCNmediated MYCN ⁄ NCYM transcription is highly constrained in mammals (Fig. S10) , NCYM coding sequences are conserved only in humans and monkeys. (6) Therefore, the transcriptional regulation of MYCN by OCT4 and the positive autoregulation of MYCN may have evolved before the emergence of the NCYM gene, and NCYM strengthens the MYCN-OCT4 network by stabilizing MYCN, thereby inducing OCT4 transcription. NCYM is positively selected during evolution; (6) however, its physiological roles in normal stem cells have remained unknown. Because new genes have been reported to rapidly become essential after emergence, (27, 28) future studies will need to examine the physiological roles of the MYCN ⁄ NCYM-OCT4 networks in the maintenance of human normal stem cells.
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